Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial

This study uses the results of the FOURIER trial to assess the current cost-effectiveness of PCSK9 inhibitors over the lifetime analytic horizon for patients with atherosclerotic cardiovascular disease in the United States.

Saved in:
Bibliographic Details
Published in:JAMA : the journal of the American Medical Association 2017-08, Vol.318 (8), p.748-750
Main Authors: Kazi, Dhruv S, Penko, Joanne, Coxson, Pamela G, Moran, Andrew E, Ollendorf, Daniel A, Tice, Jeffrey A, Bibbins-Domingo, Kirsten
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - economics
Antibodies, Monoclonal - therapeutic use
Anticholesteremic Agents - economics
Anticholesteremic Agents - therapeutic use
Cardiovascular Diseases - prevention & control
Cholesterol, LDL - blood
Cost-Benefit Analysis
Drug Costs
Drug Therapy, Combination
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Hypercholesterolemia - drug therapy
Hypercholesterolemia - economics
Letter
Letters
Proprotein Convertase 9 - antagonists & inhibitors
Quality-Adjusted Life Years
Research Letter
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study uses the results of the FOURIER trial to assess the current cost-effectiveness of PCSK9 inhibitors over the lifetime analytic horizon for patients with atherosclerotic cardiovascular disease in the United States.
ISSN:0098-7484
1538-3598
DOI:10.1001/jama.2017.9924